Table 2 |
||||
|
Specificity of IgG antibodies for block 4 allelic forms in each study population and in all study populationsa |
||||
|
Block 4 Peptide(s) |
Colombia |
Papua New Guinea |
Cameroon |
Total |
|
|
||||
|
1 |
9% |
20% |
9% |
13% |
|
2 |
68 |
15 |
27 |
40 |
|
3 |
9 |
0 |
0 |
6 |
|
4 |
4.5 |
0 |
27 |
7 |
|
1+2 |
4.5 |
5 |
0 |
4 |
|
1+3 |
0 |
5 |
0 |
2 |
|
1+4 |
0 |
5 |
9 |
4 |
|
2+3 |
0 |
0 |
0 |
0 |
|
2+4 |
4.5 |
10 |
9 |
7 |
|
3+4 |
0 |
0 |
0 |
0 |
|
1+2+3 |
0 |
10 |
9 |
6 |
|
1+2+4 |
0 |
10 |
9 |
6 |
|
1+3+4 |
0 |
0 |
0 |
0 |
|
2+3+4 |
0 |
5 |
0 |
2 |
|
1+2+3+4 |
0 |
15 |
0 |
6 |
|
|
||||
|
aPercent positive based on IgG samples reacting with one or more block 4 peptides: 22/111 samples from Colombia, 19/22 from PNG, and 11/61 from Cameroon. Total: Percent positive based on a total of 52 responders from all groups |
||||
|
Chang et al. Malaria Journal 2010 9:14 doi:10.1186/1475-2875-9-14 |
||||
